Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 9:ciaf354.
doi: 10.1093/cid/ciaf354. Online ahead of print.

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept

Affiliations

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept

Nandita Nadig et al. Clin Infect Dis. .

Abstract

This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of abatacept in hospitalized adults with severe or critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.

Keywords: COVID-19; SARS-CoV-2; abatacept; guideline.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. Evaluation of relationships as potential conflicts of interest (COI) is determined by a review process. The assessment of disclosed relationships for possible COIs is based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). No panelists had COIs directly related to abatacept. The following panelists have scientific advisory/consultant roles not related to the topic of COVID-19 with indicated companies: R. B. with Merck and Gilead, E. S. D. with Gilead, D. V. G. with Merck and Gilead, S. S. with Pfizer (concluded), P. T. with Merck, and R. G. with Merck. The following panelists have scientific advisory/consultant roles related to COVID-19 but not severe/critical COVID-19 with indicated companies: R. B. with Shionogi, K. C. with Pardes Biosciences (concluded), A. Y. K. with Shionogi, S. S. with Adamis and Immunome (concluded), and P. T. with Shionogi. J. C. P. had a scientific advisory/consultant role (concluded) with InflaRx related to vilobelimab for critical COVID-19. No disclosures were reported for all other authors (the majority of panelists), including chair and vice chair. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

LinkOut - more resources